L6545

Letrozol

≥98% (HPLC), powder, non-steroidal aromatase inhibitor

• Synonym(e): 4,4′-(1H-1,2,4-Triazol-1-ylmethylen)-bisbenzonitril
• Empirische Formel (Hill-System): C₁₇H₁₁N₅
• CAS-Nummer: 112809-51-5
• Molekulargewicht: 285.30
• UNSPSC Code: 51111800
• PubChem Substance ID: 329817641
• NACRES: NA.77
• MDL number: MFCD00866241
• Assay: ≥98% (HPLC)
• Form: powder

Eigenschaften

• Produktname: Letrozol, ≥98% (HPLC)
• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• color: white to off-white
• solubility: DMSO: >50 mg/mL
• originator: Novartis
• storage temp.: 2-8°C
• SMILES string: N#CC(C=C1)=CC=C1C(N2C=NC=N2)C3=CC=C(C#N)C=C3
• InChI: 1S/C17H11N5/c18-9-13-1-5-15(6-2-13)17(22-12-20-11-21-22)16-7-3-14(10-19)4-8-16/h1-8,11-12,17H
• InChI key: HPJKCIUCZWXJDR-UHFFFAOYSA-N
• Gene Information: human ... CYP19A1(1588)

Beschreibung

Application

Letrozole has been used:

• in organoid growth assay to determine its inhibitory capacity(48)
• to investigate steroid receptor coactivator-1 (SRC-1) mediated endogenous estrogen regulation of hippocampal PSD-95(49)
• to determine its effects on tumor-induced hyperalgesia(50)
• for hormonal manipulation in rats(51)
• to study its effects on lipocalin-2 (Lcn2)(52)
• to determine its effects on mechanical hyperalgesia and aromatase expression(53)

Biochem/physiol Actions

Letrozole acts as an adjuvant agent and is used to treat breast cancer.

Letrozol ist ein nicht-steroidaler Aromatase-Inhibitor der dritten Generation. Es ist ein kompetitiver Inhibitor des Aromatase Enzymsystems und verhindert so die Umwandlung von Androgenen zu Östrogenen. Letrozol hemmt Aromatase durch kompetitive Bindung an das Häm der Cytochrom-P450-Untereinheit des Enzyms, was zu einer Abnahme der Östrogen-Biosynthese in allen Geweben führt.

Letrozol ist ein nicht-steroidaler Aromatase-Inhibitor.

Features and Benefits

This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Sicherheitshinweise

• pictograms: GHS08
• signalword: Warning
• hcodes: H361fd,H373
• pcodes: P202 - P260 - P280 - P308 + P313 - P405 - P501
• Hazard Classifications: Repr. 2 - STOT RE 2
• Lagerklasse: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable